지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한뇌혈관외과학회 Journal of Cerebrovascular and Endovascular Neurosurgery Journal of Cerebrovascular and Endovascular Neurosurgery Vol.25 No.2
- 발행연도
- 2023.6
- 수록면
- 132 - 142 (11page)
- DOI
- 10.7461/jcen.2023.E2022.10.009
이용수
초록· 키워드
오류제보하기
Objective: Dual antiplatelet therapy (DAPT) is usually temporarily used after stent-assisted coil embolization (SACE), and is commonly converted to mono antiplatelet therapy (MAPT) for indefinitely. In this study, we aimed to find the possibility of discontinuing MAPT, and to determine the proper period of DAPT use.Methods: We used the Standard Sample Cohort DB dataset from the National Health Insurance Sharing Service. Among approximately 1 million people in the dataset, SACE was performed in 214 patients whose data this study analyzed. The relationship between discontinuation of antiplatelet therapy and intracranial hemorrhage or cerebral infarction was analyzed using multiple logistic regression, considering all confounding variables. The survival rate according to the continuation of antiplatelet therapy was obtained using Kaplan-Meier analysis, and the difference in survival rate according to the continuation of antiplatelet therapy was verified using the log-rank test. The hazard ratio according to continuation of antiplatelet therapy was obtained using the Cox proportional hazards model. The analysis was conducted by applying the same statistical method to the duration of DAPT use.Results: Among 214 patients who underwent SACE, 50, 159 and five patients continued, discontinued and did not use antiplatelet therapy (except at the time of procedure), respectively. In multiple logistic regression analysis, discontinuation of antiplatelet agents (including aspirin) and the period of DAPT use did not affect the occurrence of intracranial hemorrhage or cerebral infarction, considering various confounding factors. In the survival analysis according to the continuation of antiplatelet agents, patients who continued to use antiplatelet agents had a higher survival rate than those in other groups (p=0.00). The survival rate was higher in the rest of the group than in the group that received DAPT for three months (p=0.00).Conclusions: Continuation of antiplatelet agents or the period of DAPT use did not affect the occurrence of intracranial hemorrhage or cerebral infarction. Considering the survival rate, it would be better to maintain at least three months of antiplatelet therapy and it might be recommended to continue DAPT use for 12 months.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Association of Mortality with Antiplatelet Treatment in Patients with Stent Placement or Angioplasty: A Population-Based Nested Case-Control Study
Yonsei Medical Journal
2021 .01
-
외상성 급성 경막하출혈 환자에서의 단일 항혈소판제 요법 및 이중 항혈소판제 요법에 따른 출혈량 변화에 대한 고찰
대한응급의학회지
2024 .06
-
경피적 관상동맥중재술 이후 항혈소판제 사용의 경제성 평가 연구: 체계적 문헌고찰
보건의료기술평가
2022 .12
-
Variability of Platelet Reactivity on Antiplatelet Therapy in Neurointervention Procedure
대한신경외과학회지
2019 .01
-
항혈소판제를 투여받는 환자의 치과치료
대한치과의사협회지
2019 .09
-
Preoperative Cessation of Both Dual Anti-Platelet Agents Is Safe after 1 Year in Patients Receiving Percutaneous Coronary Intervention
지질·동맥경화학회지
2020 .01
-
Evaluation of Bleeding After Denal Extraction in Patients Taking Single Antiplatelet Treatment
International Journal of Oral Biology
2015 .09
-
Determinants and Clinical Outcomes of Extended Dual Antiplatelet Therapy over 3 Years after Drug-Eluting Stent Implantation: A Retrospective Analysis
Yonsei Medical Journal
2020 .01
-
The Role of Novel Oral Anticoagulants and Antiplatelet Therapy after Percutaneous Coronary Intervention: Individualizing Therapy to Optimize Outcomes
Korean Circulation Journal
2019 .01
-
Prestroke Antiplatelet Effect on Symptomatic Intracranial Hemorrhage and Functional Outcome in Intravenous Thrombolysis
대한뇌졸중학회지
2016 .01
-
The Use Pattern and Clinical Impact of New Antiplatelet Agents Including Prasugrel and Ticagrelor on 30-day Outcomes after Acute Myocardial Infarction in Korea: Korean Health Insurance Review and Assessment Data
Korean Circulation Journal
2017 .01
-
항혈소판제와 비스테로이드성소염진통제의 동시 투약으로 인한 출혈 사례
한국임상약학회지
2018 .01
-
Is Taking an Antiplatelet Agent a Contraindication for Early Surgery in Displaced Femur Neck Fracture?
Hip and Pelvis
2015 .01
-
Efficacy of dual antiplatelet therapy as premedication before diagnostic cerebral digital subtraction angiography
Journal of Cerebrovascular and Endovascular Neurosurgery
2019 .01
-
Continuous Use of Thienopyridine May Be as Safe as Low-Dose Aspirin in Endoscopic Resection of Gastric Tum
Gut and Liver
2018 .01
-
Antithrombotic and Antiplatelet Activities of MH32
한국실험동물학회 학술발표대회 논문집
2015 .08
-
The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and “Asian Paradox”
Korean Circulation Journal
2018 .01
-
Early Neurological Deterioration and Time to Start Dual Antiplatelet Therapy in Patients With Acute Mild-to-Moderate Ischemic Stroke: A Pre-Specified Post Hoc Analysis of the ATAMIS Trial
대한뇌졸중학회지
2024 .09
-
Antiplatelet therapy within 24 hours of tPA: lessons learned from patients requiring combined thrombectomy and stenting for acute ischemic stroke
Journal of Cerebrovascular and Endovascular Neurosurgery
2020 .01
-
Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus
Diabetes and Metabolism Journal
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0